AFP
LUCD icon

Ausdal Financial Partners’s Lucid Diagnostics LUCD Stock Holding History

Ausdal Financial Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Hold
12,075
– – ﹤0.01% 1040
2026
Q1 		$13.9K Buy
+12,075
New +$15.4K ﹤0.01% 982

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ausdal Financial Partners's LUCD Position: Q2 2026 in Review

Ausdal Financial Partners held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 12,075 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Ausdal Financial Partners first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.9K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Ausdal Financial Partners held 12,075 shares of Lucid Diagnostics worth $12.9K as of Q2 2026.
  • Ausdal Financial Partners left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Ausdal Financial Partners's portfolio in Q2 2026, its #1040 holding.
  • Ausdal Financial Partners first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • Ausdal Financial Partners's Lucid Diagnostics position peaked at $13.9K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.